

Centers for Disease Control and Prevention (CDC) Atlanta GA 30341-3724

March 16, 2016

Dominic Mancini Deputy Director Office of Information and Regulatory Affairs Office of Management and Budget Washington, DC

Subject: Request for Emergency Review and Clearance

Dear Mr. Mancini:

Pursuant to Office of Management and Budget (OMB) procedures established at 5 CFR Part 1320, Controlling Paperwork Burdens on the Public, I request that the proposed information collection project, "Emergency zika package II: Persistence of zika virus in body fluids and case-control investigation of etiologic agents associated with Guillain-Barré Syndrome" be processed in accordance with section 1320.13, Emergency Processing.

I have determined that this information must be collected prior to the expiration of time periods established under Part 1320, and that this information is essential to the CDC's mission to protect America from health, safety and security threats, both foreign and in the U.S. The purpose of this information collection is to assess the prevalence and duration of Zika virus RNA in body fluids and to identify potential risk factors for the development of Guillain-Barré Syndrome. This information will allow the CDC to target and refine public health interventions to arrest the spread of Zika virus.

CDC cannot reasonably comply with the normal clearance procedures because CDC researchers need to begin research on the persistence of Zika virus in body fluids and the association of Zika virus with GBS right away in order to increase the health security of the United States. Therefore, CDC requests a 180-day emergency clearance to carry out these two investigations.

Please provide an approval/disapproval determination of this request to collect information under an emergency clearance by close of business March 21, 2016.

Respectfully,

Beth P. Bell, MD, MPH/

Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC)